Article

Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease.

Department of Neurology and the Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA.
NeuroRx 05/2005; 2(2):348-60. DOI: 10.1602/neurorx.2.2.348
Source: PubMed

ABSTRACT The pathophysiologic process leading to neurodegeneration in Alzheimer's disease (AD) is thought to begin long before clinical symptoms develop. Existing therapeutics for AD improve symptoms, but increasing efforts are being directed toward the development of therapies to impede the pathologic progression of the disease. Although these medications must ultimately demonstrate efficacy in slowing clinical decline, there is a critical need for biomarkers that will indicate whether a candidate disease-modifying therapeutic agent is actually altering the underlying degenerative process. A number of in vivo neuroimaging techniques, which can reliably and noninvasively assess aspects of neuroanatomy, chemistry, physiology, and pathology, hold promise as biomarkers. These neuroimaging measures appear to relate closely to neuropathological and clinical data, such as rate of cognitive decline and risk of future decline. As this work has matured, it has become clear that neuroimaging measures may serve a variety of potential roles in clinical trials of candidate neurotherapeutic agents for AD, depending in part on the question of interest and phase of drug development. In this article, we review data related to the range of neuroimaging biomarkers of Alzheimer's disease and consider potential applications of these techniques to clinical trials, particularly with respect to the monitoring of disease progression in trials of disease-modifying therapies.

0 Bookmarks
 · 
105 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The treatment of ventral hernias (VH) has been a challenging problem for medical care. Repair of these hernias is fraught with failure; recurrence rates ranging from 24-43% have been reported, even with the use of biocompatible mesh. Currently, computed tomography (CT) is used to guide intervention through expert, but qualitative, clinical judgments; notably, quantitative metrics based on image-processing are not used. We propose that image segmentation methods to capture the three-dimensional structure of the abdominal wall and its abnormalities will provide a foundation on which to measure geometric properties of hernias and surrounding tissues and, therefore, to optimize intervention. To date, automated segmentation algorithms have not been presented to quantify the abdominal wall and potential hernias. In this pilot study with four clinically acquired CT scans on post-operative patients, we demonstrate a novel approach to geometric classification of the abdominal wall and essential abdominal features (including bony landmarks and skin surfaces). Our approach uses a hierarchical design in which the abdominal wall is isolated in the context of the skin and bony structures using level set methods. All segmentation results were quantitatively validated with surface errors based on manually labeled ground truth. Mean surface errors for the outer surface of the abdominal wall was less than 2mm. This approach establishes a baseline for characterizing the abdominal wall for improving VH care.
    Proc SPIE 03/2013; 8669.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The increasing number of afflicted individuals with late-onset Alzheimer's disease (AD) poses significant emotional and financial burden on the world's population. Therapeutics designed to treat symptoms or alter the disease course have failed to make an impact, despite substantial investments by governments, pharmaceutical industry, and private donors. These failures in treatment efficacy have led many to believe that symptomatic disease, including both mild cognitive impairment (MCI) and AD, may be refractory to therapeutic intervention. The recent focus on biomarkers for defining the preclinical state of MCI/AD is in the hope of defining a therapeutic window in which the neural substrate remains responsive to treatment. The ability of biomarkers to adequately define the at-risk state may ultimately allow novel or repurposed therapeutic agents to finally achieve the disease-modifying status for AD. In this review, we examine current preclinical AD biomarkers and suggest how to generalize their use going forward.
    Alzheimer's and Dementia 06/2014; 10(3):S196–S212. · 17.47 Impact Factor
  • Source
    Revista chilena de neuro-psiquiatría. 03/2008; 46(1):55-62.

Full-text (2 Sources)

Download
59 Downloads
Available from
Jun 2, 2014